Development of bococizumab, a humanized monoclonal antibody binding proprotein convertase subtilisin kexin type 9 (PCSK9), was discontinued by Pfizer in November 2016. Please see the related summary on the Specialist Pharmacy Service website for further information (link below).
The results from two studies of bococizumab in patients with high cardiovascular risk, that were stopped prematurely following the decision to discontinue its development, are reported in the same issue of the New England Journal of Medicine.